
AbbVie presents new long-term data on IBD treatments SKYRIZI and RINVOQ at UEG Week 2026
AbbVie unveiled 20 new scientific presentations at the 2026 United European Gastroenterology Week, highlighting long-term and real-world data for its inflammatory bowel disease (IBD) treatments SKYRIZI (risankizumab) and RINVOQ (upadacitinib). The da...





